[go: up one dir, main page]

AR027956A1 - Nuevas combinaciones de farmacos - Google Patents

Nuevas combinaciones de farmacos

Info

Publication number
AR027956A1
AR027956A1 ARP010100838A ARP010100838A AR027956A1 AR 027956 A1 AR027956 A1 AR 027956A1 AR P010100838 A ARP010100838 A AR P010100838A AR P010100838 A ARP010100838 A AR P010100838A AR 027956 A1 AR027956 A1 AR 027956A1
Authority
AR
Argentina
Prior art keywords
pharmacos
combinations
new
pharmacos combinations
new pharmacos
Prior art date
Application number
ARP010100838A
Other languages
English (en)
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of AR027956A1 publication Critical patent/AR027956A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Anesthesiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Cardiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ARP010100838A 2000-02-24 2001-02-23 Nuevas combinaciones de farmacos AR027956A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18479000P 2000-02-24 2000-02-24

Publications (1)

Publication Number Publication Date
AR027956A1 true AR027956A1 (es) 2003-04-16

Family

ID=22678338

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010100838A AR027956A1 (es) 2000-02-24 2001-02-23 Nuevas combinaciones de farmacos

Country Status (16)

Country Link
US (1) US20020010216A1 (es)
EP (1) EP1257277B1 (es)
JP (1) JP2003523382A (es)
CN (2) CN1660435A (es)
AR (1) AR027956A1 (es)
AT (1) ATE297735T1 (es)
AU (1) AU781254B2 (es)
CA (1) CA2399442A1 (es)
DE (1) DE60111500T2 (es)
DK (1) DK1257277T3 (es)
ES (1) ES2241802T3 (es)
MX (1) MXPA02008183A (es)
NZ (1) NZ520975A (es)
PE (1) PE20011306A1 (es)
PT (1) PT1257277E (es)
WO (1) WO2001062236A2 (es)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090087135A (ko) 1999-07-01 2009-08-14 파마시아 앤드 업존 캄파니 엘엘씨 고선택성 노르에피네프린 재흡수 억제제 및 그의 이용 방법
EP1629843A3 (en) * 1999-07-01 2006-03-15 Pharmacia & Upjohn Company LLC Reboxetine for treating chronic fatigue syndrome
US20030087965A1 (en) * 2001-07-31 2003-05-08 Robertson David W. Treatment of chronic pain with 3-aryloxy-3-phenylpropanamines
US7183410B2 (en) * 2001-08-02 2007-02-27 Bidachem S.P.A. Stable polymorph of flibanserin
US20030060475A1 (en) * 2001-08-10 2003-03-27 Boehringer Ingelheim Pharma Kg Method of using flibanserin for neuroprotection
DE10146275A1 (de) * 2001-09-18 2003-04-24 Gruenenthal Gmbh Kombination ausgewählter Opioide mit Muscarin-Antagonisten zur Therapie der Harninkontinenz
DE10149674A1 (de) 2001-10-09 2003-04-24 Apogepha Arzneimittel Gmbh Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
US6602911B2 (en) 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
US20030185882A1 (en) * 2001-11-06 2003-10-02 Vergez Juan A. Pharmaceutical compositions containing oxybutynin
US8329217B2 (en) 2001-11-06 2012-12-11 Osmotica Kereskedelmi Es Szolgaltato Kft Dual controlled release dosage form
WO2003047560A1 (en) * 2001-11-30 2003-06-12 Eli Lilly And Company Use of norepinephrine reuptake inhibitors for the treatment of tic disorders
AU2003213009A1 (en) * 2002-02-12 2003-09-04 Cypress Bioscience, Inc. Methods of treating attention deficit/hyperactivity disorder (adhd)
US20030203055A1 (en) * 2002-03-15 2003-10-30 Cypress Bioscience, Inc. Methods of treating visceral pain syndromes
US7754242B2 (en) * 2002-03-20 2010-07-13 Alkermes, Inc. Inhalable sustained therapeutic formulations
AU2003226751A1 (en) * 2002-03-28 2003-10-13 Synthon B.V. Low water-soluble venlafaxine salts
AU2003221535A1 (en) * 2002-03-28 2003-10-13 Synthon B.V. Venlafaxine besylate
US20040048877A1 (en) * 2002-05-22 2004-03-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions containing flibanserin
US20050226926A1 (en) 2002-07-25 2005-10-13 Pfizer Inc Sustained-release tablet composition of pramipexole
US20070196481A1 (en) * 2002-07-25 2007-08-23 Amidon Gregory E Sustained-release tablet composition
US8679533B2 (en) * 2002-07-25 2014-03-25 Pharmacia Corporation Pramipexole once-daily dosage form
AU2003268361A1 (en) * 2002-08-30 2004-03-19 Watson Pharmaceuticals, Inc. Drug delivery system for treating urinary incontinence
EP1558231A4 (en) * 2002-10-03 2010-09-08 Cypress Bioscience Inc DOSAGE CLIMBING AND FRICTIONAL DAILY DOSE OF ANTIDEPRESSANTS TO TREAT NEUROLOGICAL DISORDERS
US6974820B2 (en) * 2002-11-06 2005-12-13 Bridge Pharma, Inc. Methods for treating urinary incontinence and other disorders using trospium
EP1424079A1 (en) * 2002-11-27 2004-06-02 Boehringer Ingelheim International GmbH Combination of a beta-3-receptor agonist and of a reuptake inhibitor of serotonin and/or norepinephrine
US20040204411A1 (en) * 2002-12-17 2004-10-14 Pharmacia Corporation Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of reboxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
AU2003290363A1 (en) * 2002-12-24 2004-07-22 Amedis Pharmaceuticals Ltd. Therapeutic use of selective noradrenaline reuptake inhibitors
US6943193B1 (en) * 2003-01-21 2005-09-13 Jordan A. Altabet Method for treating sexual dysfunction
RU2317817C2 (ru) 2003-02-14 2008-02-27 Пьер Фабр Медикаман Применение (1s,2r) энантиомера милнаципрана для получения лекарственного средства
FR2851163B1 (fr) 2003-02-14 2007-04-27 Utilisation de l'enantiomere dextrogyre du milnacipran pour la preparation d'un medicament
US6846823B2 (en) * 2003-04-04 2005-01-25 Dynogen Pharmaceuticals, Inc. Method of treating lower urinary tract disorders
US20050009862A1 (en) * 2003-04-25 2005-01-13 Sabounjian Luann Method for promoting uninterrupted sleep by administration of trospium chloride
CA2536161A1 (en) * 2003-08-27 2005-03-10 Eli Lilly And Company Treatment of pervasive developmental disorders with norepinephrine reuptake inhibitors
US7410978B2 (en) 2003-11-04 2008-08-12 Supernus Pharmaceuticals, Inc. Once daily dosage forms of trospium
CA2536401C (en) 2003-11-04 2011-08-30 Shire Laboratories Inc. Compositions of quaternary ammonium compounds containing bioavailability enhancers
US20050239798A1 (en) * 2004-04-22 2005-10-27 Boehringer Ingelheim Pharmaceuticals, Inc. Method for the treatment of premenstrual and other female sexual disorders
ATE486588T1 (de) * 2004-08-13 2010-11-15 Boehringer Ingelheim Int Tablettenformulierung mit verlängerter freisetzung mit pramipexol oder einem pharmazeutisch zulässigen salz davon, herstellungsverfahren und verwendung dafür
EP2431027A1 (en) * 2004-08-13 2012-03-21 Boehringer Ingelheim International GmbH Extended release pellet formulation containing Pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
CA2599937A1 (en) * 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of anxiety disorders
US20060293309A1 (en) * 2005-03-28 2006-12-28 Dynogen Pharmaceuticals, Inc. Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors
US7390816B2 (en) * 2005-06-21 2008-06-24 Bridge Pharma, Inc. Methods for treating urinary incontinence in patients suffering from memory disorders
US20060287347A1 (en) * 2005-06-21 2006-12-21 Aberg A K G Methods for treating smooth muscle disorders using trospium
US20070004766A1 (en) * 2005-07-01 2007-01-04 Aberg A K G Methods for relaxation of smooth muscle contractions using Trospium
ES2646326T3 (es) 2005-08-03 2017-12-13 Sprout Pharmaceuticals, Inc. Uso de flibanserina en el tratamiento de la obesidad
US7994220B2 (en) * 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
CA2626134C (en) 2005-10-29 2013-12-24 Boehringer Ingelheim International Gmbh Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
US20070105869A1 (en) * 2005-11-08 2007-05-10 Stephane Pollentier Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
US20090098202A1 (en) * 2006-02-10 2009-04-16 Boehringer Ingelheim International Gmbh Extended Release Formulation
JP2009526021A (ja) * 2006-02-10 2009-07-16 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 放出を加減した製剤
NZ573382A (en) * 2006-05-09 2012-02-24 Boehringer Ingelheim Int Use of flibanserin for the treatment of post-menopausal sexual desire disorders
ATE456369T1 (de) 2006-06-30 2010-02-15 Boehringer Ingelheim Int Flibanserin zur behandlung von harninkontinenz und assoziierten erkrankungen
CA2657043A1 (en) * 2006-07-14 2008-01-17 Boehringer Ingelheim International Gmbh Use of flibanserin for the treatment of sexual disorders in females
CL2007002214A1 (es) 2006-08-14 2008-03-07 Boehringer Ingelheim Int Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
AU2007286288A1 (en) 2006-08-14 2008-02-21 Boehringer Ingelheim International Gmbh Formulations of flibanserin and method for manufacturing the same
BRPI0716436B8 (pt) * 2006-08-25 2021-05-25 Boehringer Ingelheim Int sistema de liberação controlada e método para fabricação do mesmo
US20080081067A1 (en) * 2006-10-03 2008-04-03 Gupta Manishkumar Sustained release pharmaceutical compositions of venlafaxine and process for preparation thereof
US8304601B2 (en) * 2007-01-23 2012-11-06 Keiko Fujikawa Mouse model for eye disease
US8871275B2 (en) 2007-08-08 2014-10-28 Inventia Healthcare Private Limited Extended release compositions comprising tolterodine
CL2008002693A1 (es) * 2007-09-12 2009-10-16 Boehringer Ingelheim Int Uso de flibanserina para el tratamiento de sintomas vasomotores seleccionados de sofocos, sudores nocturnos, cambios de estado de animo e irritabilidad
IT1392333B1 (it) * 2008-12-16 2012-02-28 Giofarma S R L Preparazione farmaceutica per il trattamento di patologie depressive, contenente una proteina con elevato rapporto triptofano/lnaa
US10265311B2 (en) 2009-07-22 2019-04-23 PureTech Health LLC Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
EP3061821B1 (en) 2009-07-22 2019-07-10 Puretech Health LLC Compositions for treatment of disorders ameliorated by muscarinic receptor activation
JP2013510176A (ja) 2009-11-06 2013-03-21 ピエール ファーブル メディカモン （１ｓ，２ｒ）−２−（アミノメチル）−ｎ，ｎ−ジエチル−１−フェニルシクロプロパンカルボキサミドの新規結晶形態
JP6196551B2 (ja) * 2010-04-12 2017-09-13 スパーナス ファーマシューティカルズ インコーポレイテッド ビロキサジン塩を製造する方法及びその新規な多形
US20120289744A1 (en) 2010-11-03 2012-11-15 Arch Pharmalabs Limited Process for preparing optically pure milnacipran and its pharmaceutically acceptable salts
GEAP202416602A (en) * 2017-04-28 2024-10-10 Brigham & Womens Hospital Inc Methods and compositions for treating sleep apnea
LT3746126T (lt) 2018-01-30 2024-10-25 Apnimed, Inc. (Delaware) Miego apnėjos arba paprasto knarkimo gydymui skirti būdai ir kompozicijos
US20190381056A1 (en) 2018-06-17 2019-12-19 Axsome Therapeutics, Inc. Compositions for delivery of reboxetine
EP3856182B1 (en) 2018-09-28 2025-12-24 Karuna Therapeutics, Inc. Compositions and methods for treating disorders ameliorated by muscarnic receptor activation
US11020402B2 (en) 2018-10-15 2021-06-01 Axsome Therapeutics, Inc. Use of reboxetine to treat narcolepsy
US20200147093A1 (en) 2018-10-15 2020-05-14 Axsome Therapeutics, Inc. Use of esreboxetine to treat nervous system disorders such as fibromyalgia
CA3117766A1 (en) * 2018-10-31 2020-05-07 Apnimed, Inc. (Delaware) Methods and compositions for treating sleep apnea
IL297877A (en) 2020-05-05 2023-01-01 Apnimed Inc Delaware Polymorphic forms of (r)-oxybutynin hydrochloride

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2002492A1 (en) * 1988-11-11 1990-05-11 Sandra T. A. Malkowska Pharmaceutical ion exchange resin composition
GB9517883D0 (en) * 1995-09-01 1995-11-01 Euro Celtique Sa Improved pharmaceutical ion exchange resin composition

Also Published As

Publication number Publication date
WO2001062236A2 (en) 2001-08-30
JP2003523382A (ja) 2003-08-05
CN1660435A (zh) 2005-08-31
US20020010216A1 (en) 2002-01-24
EP1257277B1 (en) 2005-06-15
WO2001062236A3 (en) 2002-03-07
NZ520975A (en) 2004-03-26
AU781254B2 (en) 2005-05-12
DK1257277T3 (da) 2005-09-12
DE60111500D1 (de) 2005-07-21
CN1396829A (zh) 2003-02-12
CA2399442A1 (en) 2001-08-30
MXPA02008183A (es) 2002-11-29
PE20011306A1 (es) 2001-12-29
DE60111500T2 (de) 2006-05-18
AU3802801A (en) 2001-09-03
PT1257277E (pt) 2005-09-30
ES2241802T3 (es) 2005-11-01
ATE297735T1 (de) 2005-07-15
EP1257277A2 (en) 2002-11-20

Similar Documents

Publication Publication Date Title
AR027956A1 (es) Nuevas combinaciones de farmacos
PT1259508E (pt) Novos biarilcarboxamidas
ATE290000T1 (de) Muscarinagonisten
DE10136334B8 (de) Hochgeschwindigkeitsvertikalresonatoroberflächenemissionslaser
ATE312098T1 (de) Thiazinoxazolidinon
ATA2932001A (de) Schneefräse
DE50100710D1 (de) Wischblatt
ATE262530T1 (de) Indolochinazolinone
ATE298751T1 (de) 7-oxopyridoryrimidine
PT1268453E (pt) Metabolitos de agonista/antagonista de estrogenio
DE10192638T1 (de) Bohrstangenladevorrichtung
DE60118868D1 (de) Turbomaschinenleitschaufel
ATE509008T1 (de) Sulfonylguanidine
DE10196064T1 (de) Halbleiterfotodektionsgerät
DE50011511D1 (de) Blowby-Heizung
PT1317179E (pt) Formulacoes de mesotriona
DE10052925B4 (de) Schaukelbett
DE50007634D1 (de) Kardioplegieballonkatheter
ATE476423T1 (de) Benzoylpyridazine
DE10195909T1 (de) Viehfüttervorrichtung
DE10085445T1 (de) Drahterodierbearbeitungseinrichtung
DE10195992T1 (de) Oberflächenendbearbeitungsbelag
ATE284887T1 (de) Thienopyrrolidinone
DE50010192D1 (de) Intaglio-druckmaschine
DE10054120B4 (de) Aufsparrendämmelement

Legal Events

Date Code Title Description
FB Suspension of granting procedure